Made With Uberflip Content Marketing

BIO-Europe Spring 2017

The process of bringing a pharmaceutical drug to market once a lead compound has been identified: from drug discovery, funding, clinical trials, FDA approvals, and partnerships

  • BIO Report: Funding cools down after five-year run while early deals stay hot

    BIO Report: Funding cools down after five-year run while early deals stay hot

    Across five metrics for biotech financings tracked by BIO, the sector saw steep drops in 2016 due to uncertainty introduced by political upheavals and regulatory reforms. Yet in each category the...

    Read
  • Join us at BIO-Europe Spring 2017 this March

    Learn More
  • Biotechs successfully navigate alternative paths to financing

    Biotechs successfully navigate alternative paths to financing

    Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...

    Read
  • Can pharma afford to cure patients instead of treating them?

    Can pharma afford to cure patients instead of treating them?

    Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...

    Read
  • Digital medicine takes small steps toward Big Data

    Digital medicine takes small steps toward Big Data

    Across a fragmented European landscape multiple programs advance the digitization of data as building blocks for advanced analytics. Read more »

    Read
  • Mounting uncertainty threatens research and innovation in medicines

    Mounting uncertainty threatens research and innovation in medicines

    Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...

    Read
  • POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...

    Read
  • Facing increased complexity, oncology trial sites tighten up procedures

    Facing increased complexity, oncology trial sites tighten up procedures

    Financing a Phase I trial in oncology is tough, but completing a successful trial for a novel drug candidate is even tougher. An army of specialists is required, and then comes the challenge of...

    Read
  • Startup Slam: Compelling pitch for Peptomyc takes the prize

    Startup Slam: Compelling pitch for Peptomyc takes the prize

    The third round of this fast-paced parade of presentations pitted 14 promising entrepreneurs in a winner-take-all competition. The reward includes tailored mentoring with the scientists and...

    Read
  • BIO-Europe Spring 2017 kicks off this week in Barcelona

    BIO-Europe Spring 2017 kicks off this week in Barcelona

    Read
  • Innovation in an uncertain world

    Innovation in an uncertain world

    How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price anger, science skepticism, and policies to close borders and protect jobs? Read more »

    Read
  • Report gives substance to fast-paced scientific discoveries in microbiome

    Report gives substance to fast-paced scientific discoveries in microbiome

    Guest post by Eric de La Fortelle, Venture Partner at Seventure Partners Microbes are everywhere, and apart from the occasional pathogen, they are a positive force for health maintenance. Indeed...

    Read
  • Stirring the Pot for Entrepreneurship in European Tech Transfer

    Stirring the Pot for Entrepreneurship in European Tech Transfer

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. The science in many parts of Europe is first-rate. No one disputes...

    Read
  • Barcelona biotech companies shine light on regional entrepreneurship

    Barcelona biotech companies shine light on regional entrepreneurship

    Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....

    Read
  • Increase the value of your asset: Think with the end in mind

    Increase the value of your asset: Think with the end in mind

    Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...

    Read
  • Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Guest article by BIOCAT, the Bioregion of Catalonia After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22),...

    Read
  • BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans8:15

    BIO-Europe Spring® 2016: BeyondSpring Pharmaceuticals outlines Plinabulin plans

    Watch Video
  • BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech9:04

    BIO-Europe Spring® 2016: Motif's CEO on business leap from discovery to clinical-stage biotech

    Dr. Graham Lumsden, CEO of London-based biotech Motif Bio, a company focused on the development of therapeutics for infectious diseases, talks with Mike Ward, global director of content for Informa Ph

    Watch Video
  • BIO-Europe Spring® 2016: Purdue CEO outlines plans for growth away from opioid market12:39

    BIO-Europe Spring® 2016: Purdue CEO outlines plans for growth away from opioid market

    During the 2016 BIO-Europe Spring® partnering meeting in Stockholm, Sweden, Mark Timney, president and CEO of Purdue Pharma, caught up with Mike Ward, global director of content for Informa Pharma Int

    Watch Video
  • loading
    Loading More...